UK Court of Appeal concludes patent spat between dsm-firmenich and Mara Renewables

Published: 25-Feb-2026
Regulatory

The UK Court of Appeal has rejected an appeal from dsm-firmenich against a 2025 ruling that one of its patents for producing microalgal DHA oil was invalid

You need to be a subscriber to read this article.
Click here to find out more.

The UK Court of Appeal has ruled in favour of Mara Renewables in a long-running patent dispute with dsm-firmenich.

The UK Court of Appeal rejected dsm-firmenich's appeal against a 2025 court ruling that one of its patents for producing microalgal docosahexaenoic acid (DHA) oil was invalid.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • DSM-Firmenich
See more

You may also like

Ingredients

dsm-firmenich's HMO nutraceutical gets the green light in Indonesia

Read more
dsm-firmenich's GLYCARE 2FL 9000 can now be marketed and sold within Indonesia, making it the 165th country with access to the company's HMO portfolio

Trending Articles

  1. Why brands need botanicals that consumers can believe in Beatriz Ercilla, Nektium’s QA & Regulatory Director – Operations, on the growing importance of demonstrating quality and authenticity in botanical ingredients
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Proof over promise: the value of third-party verification for supplement manufacturers Although there are more than 100,000 vitamins and dietary supplements on the market, product quality can vary depending on many factors, including the ingredients they contain, how they were sourced, how the product is manufactured and more
  3. Making Nutraceuticals launches April 2026 A new free-to-attend event co-located with Making Pharmaceuticals, delivering nine conference streams, expert insight and cross-sector opportunities for nutraceutical manufacturers, suppliers and distributors
  4. FDA reverses stance to confirm NMN is lawful for use in dietary supplements The agency’s decision marks a major policy shift, overturning its previous exclusion of NMN and clarifying the ingredient’s place in the supplement market
  5. Florida study finds arsenic in children's sweets The results from the investigation generate questions for the industry about how food safety data is gathered, assessed, framed and politicised

Upcoming event

Making Nutraceuticals

21–22 April 2026 | Conference/Exhibition | Coventry, UK See all

You may also like

Ingredients

dsm-firmenich's HMO nutraceutical gets the green light in Indonesia

dsm-firmenich's GLYCARE 2FL 9000 can now be marketed and sold within Indonesia, making it the 165th country with access to the company's HMO portfolio
Ingredients

dsm-firmenich's early life HMO ingredient, GLYCARE 2FL, approved for use in India

The early life human milk oligosaccharide ingredient is suitable for infants up to six months of age, and is designed to support gut health, while closely resembling breast milk
Manufacturing

dsm-firmenich successfully defends algal omega-3 tech patent

The UK High Court deemed that dsm-firmenich's algal processing technology, which produces high-purity DHA oils, was unlawfully used by Mara Renewables Corporation
Regulatory

dsm-firmenich's human milk oligosaccharide ingredients named as novel food ingredients in the UK and EU

The HMOs can now be incorporated into a range of food-grade products, such as supplements, infant formulas and foods for medical purposes
Ingredients

dsm-firmenich receives EU approval for calcidiol as a novel food

dsm's calcidiol ingredient can raise blood vitamin D levels in weeks, assisting in healthy immune function and overall wellbeing
Regulatory

dsm-firmenich successfully defends patent directed to proprietary DHA oils

This defends their sole manufacturing rights for specific algal nutritional lipids high in DHA and omega-3
Ingredients

dsm-firmenich secures 3-fucosyllactose market access in the European Union

dsm-firmenich has secured market access for its 3-fucosyllactose (3-FL) human milk oligosaccharide (HMO) ingredient in the European Union (EU)
Subscribe now